VEGFA and gastric cancer: Finally, several studies have shown the predictive value of baseline VEGF-A for bevacizumab treatment effect on progression-free survival and/or overall survival, meaning that only patients with high VEGF-A levels may benefit from bevacizumab treatment, for example in gastric cancer [12] and metastatic breast cancer [13].